Skip to content

A study to compare two methods of giving oxygen and nebulization in children with breathing difficulty.

Evaluation Of Clinical Outcomes Using A Nebuliser-Cum-Oxygen Mask In Pediatric Respiratory Distress - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099718
Enrollment
150
Registered
2025-12-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J22- Unspecified acute lower respiratory infection

Interventions

Intervention1: Nebulizer cum oxygen mask: Use of an integrated nebulizer cum oxygen mask that allows simultaneous delivery of oxygen and nebulized medication without interruption to children with resp

Sponsors

Saveetha medical college hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children aged 1 month to 12 years presenting with mild to moderate respiratory distress, requiring both oxygen therapy and nebulization, whose parents or legal guardians provide written informed consent.

Exclusion criteria

Exclusion criteria: Children with severe respiratory distress requiring immediate ventilatory support, congenital airway anomalies, chronic lung disease, known hypersensitivity to nebulized medications, or those already on advanced respiratory support.

Design outcomes

Primary

MeasureTime frame
Time to symptom relief , Oxygen saturation stability during therapy , Overall recovery timeTimepoint: baselien, 48 hours

Secondary

MeasureTime frame
Cost-effectiveness of the integrated device, User satisfaction , Incidence of adverse events related to device useTimepoint: baseline, 48 hours,at the time of discharge

Countries

India

Contacts

Public ContactDr Dinesh kumar

Saveetha medical college hospital

navinu.smc@saveetha.com9487002379

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026